- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01567956
Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study
November 4, 2016 updated by: sigma-tau i.f.r. S.p.A.
Phase III Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment
The aim of the trial is to test safety, tolerability and efficacy of Propionyl-L-carnitine modified release tablets 1g/die in reducing the symptoms of the disease with respect to the proportion of patients with disease remission at the end of the 8 weeks of treatment.
It will also aim to investigate capability of the treatment in the maintenance of remission after four weeks of treatment interruption; histological changes will be also evaluated and finally, improvement in the overall quality of life as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) will be investigated.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Although it seems clear that an abnormal function of the colonic epithelium is the central problem causing inflammation and the unusual immunological response to the normal gut flora in inflammatory bowel disease (IBD), the actual causes of these dysfunctions are still unknown.
Short Chain Fatty Acids (SCFA) are the main fuel of the colonic epithelium, and are normally produced by the bacterial flora by fermentation of the complex carbohydrates forming non soluble fibers usually introduced with everyday diet.
Butyrate alone contributes 70% of the normal colonocyte energy.
Studies done using animal models and colonic mucosa biopsies from patients suffering form ulcerative colitis (UC) have consistently shown that a metabolic change occurs in diseased colonic mucosa, with an impairment of butyrate oxidation (and of beta-oxidation) and an energy shortage that is only incompletely compensated by oxidation of glucose and other substrates such as glutamine.
It is also well known that matrix metalloproteases production is highly increased in IBD and that serum transglutaminase activity is significantly reduced in patients with IBD.
Transglutaminases are enzymes contributing to the crosslinking of matrix proteins and the reduction seen in patients affected by IBD correlates well with the endoscopic and histopathologic grading in UC, meaning that part of the circulating enzyme is sequestered in the injured colonic tissue in the effort to re-build the extracellular matrix during the healing process.
Propionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce membrane lipid peroxidation in endothelial cells from bovine aorta and coronary vessels, to reduce the effects of hypoxia in coronary endothelial cells, and to play a role in the cardiac metabolic abnormalities that contribute to the mechanical dysfunctions leading to heart failure.
Given these properties of Propionyl-L-carnitine Hydrochloride (ST 261) and given the peroxidative damage suffered by colonocytes in UC together with their metabolic impairment, the use of this molecule for the treatment of UC seemed to be appropriate and sound, in particular as a carrier of a propionate moiety that, once transformed into succinate, enters the Kreb cycle, acting as an extra burst fuel improving the balance of energy production inside tissues.
Previous clinical experience has shown that PLC promoted complete or nearly complete regression of cutaneous trophic ulcers in a large number of vasculopathic patients refractory to all other therapies.
As far as the UC pathology is concerned, the effects of ST 261, given orally or intrarectally, were investigated at different dosages, in preclinical experimentation, either after a single trinitrobenzene sulphonic acid (TNBS) administration (acute colitis) or after repeated TNBS administrations (reactivated colitis).
The results showed a reduction in the damaged colon area both in acute model and reactivated colitis, even if the beneficial effect of restoration of TNBS-induced alterations of tissue morphology is more evident in the reactivated colitis model, particularly after oral administration.
Based on the above-described results a development plan in humans started to investigate the activity of PLC in the treatment of ulcerative colitis.
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Innsbruck, Austria, 6020
- Landeskrankenhaus-Universitätskliniken Innsbruck - Klinische Abteilung für Gastroenterologie und Hepatologie
-
Salzburg, Austria, 5010
- Krankenhaus der Barmherzigen Brüder - Abteilung für Innere Medizin
-
Vienna, Austria, 1190
- Ordinationszentrum Döbling
-
Wien, Austria, 1090
- Allgemeines Krankenhaus Wien - Universitätsklinik Klinik für Innere Medizin III
-
-
-
-
-
Creteil, France, 94010
- Centre Hospitalier Intercommunal Créteil 40 avenue de Verdun
-
Marseille, France, 13015
- Centre Hospitalier Universitaire Hôpital Nord - Service D'Hépato-Gastro-Entérologie
-
Nantes, France, 44000
- Centre Hospitalier Universitaire Hotel Dieu Service d'hépato-gastroentérologie
-
Nice cedex 3, France, 06202
- Hôpital de I´Archet 2 Service d'Hépato-Gastroentérologie et de Nutrition Clinicque, Pôle Digestif
-
Picardie, France, 80 054
- Hôpital Nord - Dept. of Gastroenterology
-
Reims cedex, France, 51092
- Hôpital Robert Debré Service et Consultation d'Hépato-Gastro-Entérologie
-
Saint-Etienne, France, 42270
- Hopital Nord - CHU de Saint-Etienne Service de Gastro-Entérologie
-
Toulouse Cedex 4, France, 31079
- Hôpital Rangueil Service de gastro-enterologie
-
Vandoeuvre Les Nancy Cedex, France, 54511
- Hôpital Brabois Service de gastro-enterologie
-
-
-
-
-
Berlin, Germany, 10117
- Charité Universitätsmedizin Berlin Universitätsklinik Charité, Campus Mitte Medizinische Poliklinik
-
Bochum, Germany, 44791
- Saint Josef Hospital Ruhr Universitaet Bochum Gudrunstraße 56
-
Braunschweig, Germany, 38126
- Klinikum Braunschweig
-
Dresden, Germany, 01307
- Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I
-
Lübeck, Germany, 23538
- Universtätsklinikum Schleswig-Holstein Gastroenterologie
-
Magdeburg, Germany, 39120
- Universitätsklinikum Magdeburg A.ö.R. Klinik für Gastroenterologie, Hepatologie und Infektiologie
-
Mannheim, Germany, 68167
- Universitätsmedizin Mannheim II. Medizinische Klinik
-
München, Germany, 80639
- Praxis Prof. Dr. med. Herbert Kellner
-
Münster, Germany, 48149
- Universitätklinikum Münster Medizinische Klinik und Poliklinik für Innere Medizin
-
Münster, Germany, 48159
- Gastroenterologische Fachpraxis am Germania Campus
-
Stade, Germany, 21682
- Elbe Klinikum Stade Innere Medizin, Abteilung Gastroenterology
-
-
-
-
-
Budapest, Hungary, 1136
- Pannonia Maganorvosi Centrum Kft.
-
Budapest, Hungary, 1076
- Fovárosi Önkormányzat Péterfy Sándor Utcai Kórház
-
Budapest, Hungary, 1083
- Semmelweis Egyetem 1st Internal Dept.
-
Budapest, Hungary, H-1088
- Semmelweis Egyetem II. Sz. Belgyogyaszati Klinika
-
Gyula, Hungary, 5700
- Békés Megyei Képviselotestület Pándy Kálmán Kórháza Semmelweis ulica 1
-
Kaposvár, Hungary, H-7400
- Kaposi Mór Megyei Oktató Kórhaz Belgyógyászati Osztály
-
Miskolc, Hungary, 3526
- Borsod Abaúj Zemplén Megyei Kórház és Egyetemi Oktató Kórház II. sz. Belgyógyászati Osztály
-
Mosonmagyaróvar, Hungary, 9200
- Karolina Kórház Rendelointézet Belgyógyászat- Gasztroenterológiai Osztály
-
Szekszárd, Hungary, 7100
- Clinfan Kft. SMO
-
Szikszó, Hungary, 3800
- CRU Hungary Kft.
-
-
-
-
-
Daugavpils, Latvia, LV-5400
- Daugavpils Central Regional Hospital
-
Riga, Latvia, LV-1002
- Paula Stradina Clinical University Hospital Gastroenterology Centre
-
Riga, Latvia, LV-1005
- Latvian Maritime Medicine Centre
-
Riga, Latvia, LV-1006
- Digestive Disease Center GASTRO
-
-
-
-
-
Kaunas, Lithuania, LT-50009
- Lietuvos sveikatos mokslu universiteto ligonine VšI Kauno klinikos Gastroenterologijos skyrius
-
Klaipeda, Lithuania, LT-92288
- Klaipedos jurininku ligonine Diagnostikos skyrius
-
Vilnius, Lithuania, LT-03215
- VšI Mykolo Marcinkeviciaus ligonines
-
Vilnius, Lithuania, LT-08661
- Vilniaus universiteto ligonine Santariškiu klinikos Hepatologijos, gastroenterologijos ir dietologijos centras
-
-
-
-
-
Ksawerów, Poland, 95-054
- Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp.J
-
Lódz, Poland, 90-153
- SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Oddzial Gastroenterologii Ogólnej i Onkologicznej
-
Olsztyn, Poland, 10-561
- Wojewódzki Szpital Specjalistyczny w Olsztynie Oddzial Gastroenterologii
-
Sopot, Poland, 81-756
- ENDOSKOPIA Sp. z o.o.
-
Warszawa, Poland, 03-580
- NZOZ Vivamed
-
Wroclaw, Poland, 53-025
- Lexmedica
-
Wroclaw, Poland, 50-556
- Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu Klinika Gastroenterologii i Hepatologii
-
Wroclaw, Poland, 51-149
- Wojewodzki Szpital Specjalistyczny im. J. Gromkowskiego we Wroclawiu Oddzial Gastroenterologii
-
Wroclaw, Poland, 53-333
- ARS MEDICA s.c., Rybak Maria, Rybak Zbigniew
-
-
-
-
-
Alcorcón, Spain, 28922
- Fundación Hospital de Alcorcón Servicio de Gastroenterología
-
Barcelona, Spain, 08022
- Centro Medico Teknon Servicio de Aparato Disgestivo
-
El Palmar, Spain, 30120
- Hospital Universitario Virgen de la Arrixaca Servicio de Digestivo
-
Madrid, Spain, 28006
- Hospital Universitario La Princesa Unidad de Hepatología, Servicio de Gastroenterologia
-
Madrid, Spain, 28046
- Hospital Universitario La Paz Servico de Gastroenterologia
-
Sabadell, Spain, 08028
- Corporació Sanitaria Parc Taulí Servicio de Digestivo
-
Santander, Spain, 39008
- Hospital Universitario Marques de Valdecilla Servicio de Digestivo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have read the Information for the Patient and signed the Informed Consent Form.
- Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed endoscopically and histologically.
- Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis), with rectal bleeding sub-score of at least 1.
- Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening assessments.
- If female, not pregnant or nursing. For women of childbearing potential, willingness to avoid a pregnancy during the treatment period and for at least 4 weeks from the last dose of drug and utilization of an efficient method of birth control for the entire duration of the trial and until the first menses after a 30-day period after the last dose of trial medication.
Exclusion Criteria:
- Crohn's disease and indeterminate colitis.
- Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.
- Use of systemic antibiotics in the last 10 days preceding the screening.
- Use of systemic Nonsteroidal anti-inflammatory drugs on a repeat basis in the last 10 days preceding the screening.
- Use of probiotics started within 10 days preceding the screening. A stable regimen from at least 10 days prior to screening is allowed but the patient must be willing to continue up to the end of the study.
- Use of immunosuppressants or biological agents within the last 6 weeks preceding the screening.
- Treatment with L-carnitine or its esters derivatives within the last 3 months.
- Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia, Campylobacter) or toxins (C.difficile).
- Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed by the investigator.
- History of colon resection.
- Diverticulitis, symptomatic diverticulosis.
- Active peptic ulcer disease.
- Proctitis (extent of inflammation < 15 cm from the anus).
- Bleeding disorders
- Rectal therapy with any therapeutic enemas or suppositories with the exception of those required for endoscopy during the 10 days preceding the screening.
- Active or chronic infection(s) or malignancies.
- Known hypersensitivity to the active ingredient and excipients of the study drug
- Patients treated with L-Carnitine or its esters derivatives during the 3 months preceding the screening phase.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Propionyl-L-Carnitine
Modified release tablets containing 500 mg of propionyl-L-carnitine
|
500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
|
Placebo Comparator: Placebo
Modified release tablets containing inert substances
|
500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of clinical/endoscopic remissions
Time Frame: End of treatment (week 8)
|
Remission will be defined according with the overall modified Mayo score (Disease Activity Index).
A score ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score >1 will be considered necessary to classify the patient in remission state.
|
End of treatment (week 8)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Rectal bleeding evaluation
Time Frame: At week 2, 6 and 8 of treatment and after 4 week follow-up
|
Evaluation will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).
|
At week 2, 6 and 8 of treatment and after 4 week follow-up
|
Change from baseline in stool frequency evaluation
Time Frame: At week 2, 6 and 8 of treatment and after 4 week follow-up
|
Evaluations will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).
|
At week 2, 6 and 8 of treatment and after 4 week follow-up
|
Histological response to the treatment
Time Frame: End of treatment (week 8)
|
Evaluated as an improvement of the histological index of at least 1 point
|
End of treatment (week 8)
|
Change from baseline in C-reactive protein (CRP) and Fibrinogen
Time Frame: End of the treatment (week 8) and after 4 week follow-up
|
End of the treatment (week 8) and after 4 week follow-up
|
|
Improvement of patients quality of life
Time Frame: End of treatment period (week8) and after 4 week follow-up
|
A validated specific questionnaire, the SIBDQ by McMaster university will be administered to evaluate changes in patients' quality of life
|
End of treatment period (week8) and after 4 week follow-up
|
Haematology
Time Frame: Baseline and end of treatment (week8)
|
Haemoglobin, Haematocrit, RBC, WBC and differential count.
|
Baseline and end of treatment (week8)
|
Electrocardiogram
Time Frame: At baseline and at the end of treatment period (week8)
|
Standard intervals (PR, RR, QRS, QT) will be collected plus all rhythm abnormalities
|
At baseline and at the end of treatment period (week8)
|
Adverse Events collection
Time Frame: 12 weeks
|
12 weeks
|
|
Serum Chemistry
Time Frame: At baseline and at the end of treatment period (week8)
|
Standard evaluation including renal and liver function, electrolytes and blood glucose
|
At baseline and at the end of treatment period (week8)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Sandro Ardizzone, MD, Head of Inflammatory Bowel Diseases Unit Hospital "Luigi Sacco" Milan - ITALY
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
January 1, 2014
Study Registration Dates
First Submitted
March 28, 2012
First Submitted That Met QC Criteria
March 29, 2012
First Posted (Estimate)
March 30, 2012
Study Record Updates
Last Update Posted (Estimate)
November 6, 2016
Last Update Submitted That Met QC Criteria
November 4, 2016
Last Verified
April 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST261DM11006
- 2011-004770-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Propionyl-L-Carnitine
-
Sigma-Tau Research, Inc.Colorado Prevention CenterCompletedPeripheral Vascular Diseases | Intermittent ClaudicationUnited States
-
sigma-tau i.f.r. S.p.A.TerminatedUlcerative ColitisNetherlands, Romania, Israel, Czech Republic, Italy, Belgium, Russian Federation, Slovakia
-
Lee's Pharmaceutical LimitedCompletedPeripheral Arterial Diseases
-
Lee's Pharmaceutical LimitedCompletedPeripheral Arterial Disease
-
Lee's Pharmaceutical LimitedNanjing Medical UniversityCompletedPeripheral Arterial DiseaseChina
-
sigma-tau i.f.r. S.p.A.CompletedUlcerative ColitisItaly, Lithuania, Poland, Russian Federation
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Ain Shams UniversityCompleted
-
Vanderbilt University Medical CenterCompletedLung Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Carnitine Nutritional DeficiencyUnited States